ImmunoGen, Inc. IMGN, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference. The presentation is scheduled for 1:30 p.m. ET on June 7, 2018.
A webcast of the presentation will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation
of antibody-drug conjugates (ADCs) to improve outcomes for cancer
patients. By generating targeted therapies with enhanced anti-tumor
activity and favorable tolerability profiles, we aim to disrupt the
progression of cancer and offer our patients more good days. We call
this our commitment to "target a better now." Our lead product
candidate, mirvetuximab soravtansine, is in Phase 3 study for folate
receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in
Phase 1b/2 testing in combination regimens. Our novel IGN candidates for
hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180530006121/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.